TAGRISSO is an EGFR TKI indicated as a monotherapy for:
Mechanism of action (MoA)
TAGRISSO is a third-generation irreversible tyrosine kinase inhibitor (TKI). TAGRISSO was specifically designed to selectively target mutated EGFR (EGFRm) proteins.1 Watch the MoA video below to learn how TAGRISSO acts by binding irreversibly to specific EGFR mutations, blocking their activity.
To view full Prescribing Information, click here.